Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Carmat TAH Early Feasibility Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04117295
Recruitment Status : Recruiting
First Posted : October 7, 2019
Last Update Posted : July 21, 2021
Sponsor:
Information provided by (Responsible Party):
Carmat SA

Brief Summary:
Feasibility study of the Carmat TAH as a treatment for transplant-eligible patients in severe, end-stage heart failure.

Condition or disease Intervention/treatment Phase
End-stage Heart Failure Device: Carmat Total Artificial Heart Not Applicable

Detailed Description:

This is a prospective, multi-center, staged feasibility study designed to assess the initial evidence of safety and performance of the Carmat TAH in the treatment of severe, end-stage heart failure. This study will include up to 7 centers in the US. The study population will include up to 10 transplant-eligible patients enrolled and implanted with the Carmat TAH.

Data collection will be recorded prior to implantation of the device and for six months following implant, then long term at 9, 12, 18 and 24 months while the patient remains on the device. Adverse events, as defined by INTERMACS, while on device support will be collected throughout the study until study closure and will be adjudicated by an independent Clinical Event Committee.

Progress reports of the clinical outcomes will be reviewed by the DSMB after implantation of each patient and every three months thereafter while any patient is supported with the device. A progress report will be sent to FDA for review after three subjects have been implanted and followed for 60 days.

The primary objective of the study is survival on an original Carmat device at 180 days post-implant or survival to cardiac transplantation if occurring before 180 days post-implant.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Carmat Total Artificial Heart Early Feasibility Study
Estimated Study Start Date : July 2021
Estimated Primary Completion Date : June 2022
Estimated Study Completion Date : June 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure

Arm Intervention/treatment
Experimental: Treatment
Subjects implanted with the Carmat TAH
Device: Carmat Total Artificial Heart
Heart replacement therapy




Primary Outcome Measures :
  1. Survival [ Time Frame: 180 days ]
    Proportion of patients surviving on the Carmat TAH


Secondary Outcome Measures :
  1. Survival without Permanent Neurologic Deficit [ Time Frame: 180 days ]
    Proportion of patients surviving post implant without a permanent disabling stroke (Modified Rankin Scale >3)

  2. Post transplant survival [ Time Frame: 30 days ]
    Proportion of patients surviving 30 days post-transplant

  3. Change in functional status [ Time Frame: 180 days ]
    New York Heart Association (NYHA) functional classification (regression scale I, II, III, IV)

  4. Change in functional status measured by the Six Minutes Walk Test [ Time Frame: 180 days ]
    The 6-min walk test is a submaximal exercise test that entails measurement of distance walked over a span of 6 minutes. The 6-minute walk distance provides a measure for integrated global response of multiple cardiopulmonary and musculoskeletal systems involved in exercise.

  5. Generic health status change [ Time Frame: 180 days ]

    Measured with the EuroQol EQ-5D questionnaire, a descriptive system of health-related quality of life states consisting of five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take one of five responses (EQ-5D-5L). The responses record five levels of severity (1:no problems; 2:slight problems; 3:moderate problems 4:severe problems; 5:extreme problems) within a particular EQ-5D dimension.

    Measured with the Kansas City Cardiomyopathy Questionnaire, a self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.


  6. Adverse Events [ Time Frame: 180 days ]
    Adverse Event Rates will be captured per the INTERMACS definitions

  7. Hospital readmission rate [ Time Frame: 180 days ]
    Rate of unplanned readmissions to the hospital



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Must be 18 years of age or older at the time of informed consent
  2. Anatomic compatibility confirmed using 3D imaging (CT-scan).
  3. Inotrope dependent (with documented attempt to wean) or cardiac Index (CI) < 2.2 L/min/m2 if inotropes are contra-indicated (heart failure due to restrictive or constrictive physiology).
  4. On Optimal Medical Management as judged by the investigator based on current Heart Failure practice guidelines (ESC/AHA).
  5. Eligible for biventricular Mechanical Circulatory Support according to ISHLT guidelines for mechanical circulatory support:

    1. Biventricular failure with at least two of the following hemodynamic/ echocardiographic measurements implying right heart failure: RVEF ≤30%; RVSWI ≤0.25mmHg*L/m2; TAPSE ≤14mm; RV-to-LV end-diastolic diameter ratio >0.72; CVP >15 mmHg; CVP-to-PCWP ratio >0.63; Tricuspid insufficiency grade 4; PAPi<2
    2. Treatment-refractory recurrent and sustained ventricular tachycardia or ventricular fibrillation in the presence of untreatable arrhythmogenic pathologic substrate.
    3. Heart failure due to restrictive or constrictive physiology (e.g., hypertrophic cardiomyopathy, cardiac amyloidosis / senile or other infiltrative heart disease).
  6. Patient has signed the informed consent, has full understanding of procedures, and is committed to following study requirements.
  7. Eligible for cardiac transplantation

Exclusion Criteria:

  1. Known intolerance to anticoagulant or antiplatelet therapies or known Heparin Induced Thrombocytopenia.
  2. Presence of any non-temporary mechanical circulatory support
  3. Presence of temporary mechanical circulatory support such as Impella (all types) or IABP with a duration greater than 21 days
  4. Presence of ECMO with a duration greater than 7 days
  5. Patient is intubated and unconscious, or intubated and not awake
  6. Coagulopathy defined by platelets < 100k/µl or INR ≥ 1.5 not due to anticoagulant therapy.
  7. Cerebrovascular accident < 3 months or symptomatic or a known > 80% carotid stenosis.
  8. Known abdominal or thoracic aortic aneurysm > 5 cm that has not been treated.
  9. Severe end-organ dysfunction as per any of the following criteria:

    1. Total bilirubin > 2.5 mg/dl or cirrhosis evidenced by ultrasound, CT-scan and positive biopsy
    2. eGFR < 30ml/min/1.73m2 or the need for chronic renal replacement therapy
  10. History of severe Chronic Obstructive Pulmonary Disease with FEV1/FVC <0.7, or FEV1<50% predicted or severe restrictive lung disease.
  11. Recent blood stream infection (<7 days).
  12. Documented amyloid light-chain (AL amyloidosis).
  13. Hemodynamically significant peripheral vascular disease with documented ankle- brachial pressure index (ABPI) <0.3.
  14. Illness, other than heart disease, that would limit survival to less than 2 years.
  15. Irreversible cognitive dysfunction, psychosocial issues or psychiatric disease, likely to impair compliance with the study protocol and TAH management that in the opinion of the investigator could interfere with the ability to manage the therapy (i.e. non-compliance to heart failure therapy, uncontrolled diabetes, mental health issue, etc.).
  16. Current or planned pregnancy or breast feeding (woman of childbearing age will have to show negative pregnancy test).
  17. Patient is currently enrolled or has participated in the last 30 days in another therapeutic or interventional clinical study that is likely to confound the study results or affect the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04117295


Contacts
Layout table for location contacts
Contact: Vanessa Gallois +33 6 38 26 88 83 vanessa.gallois@carmatsas.com
Contact: Mary Beth Kepler (734) 709-2080 marybeth.kepler@globalmedicaldeviceconsultants.com

Locations
Layout table for location information
United States, Kentucky
University of Louisville Jewish Hospital Recruiting
Louisville, Kentucky, United States, 40202
Contact: Mark S. Slaughter, MD    502-588-7622    mark.slaughter@louisville.edu   
Contact: Terry Blanton, BSN, RN    (502) 587-4381    mary.blanton@louisville.edu   
United States, North Carolina
Duke University Medical Center Recruiting
Durham, North Carolina, United States, 27710
Contact: Carmelo A. Milano, MD    919-684-3243    carmelo.milano@duke.edu   
Contact: Han Billard, MD    919-724-0343    han.billard@duke.edu   
United States, Texas
Baylor University Medical Center Recruiting
Dallas, Texas, United States, 75226
Contact: Dan M Meyer, MD    214-335-4427    Dan.Meyer@BSWHealth.org   
Contact: Frankie Negron, DC, BSN, RN    214-820-9888    Francisco.Negron@BSWHealth.org   
United States, Virginia
VCU Medical Center Recruiting
Richmond, Virginia, United States, 23298
Contact: Vigneshwar Kasirajan, MD    804-828-4639    vigneshwar.kasirajan@vcuhealth.org   
Contact: Andreea Marcu, MD    804-827-1515    andreea.marcu@vcuhealth.org   
Sponsors and Collaborators
Carmat SA
Layout table for additonal information
Responsible Party: Carmat SA
ClinicalTrials.gov Identifier: NCT04117295    
Other Study ID Numbers: CAR2019-US
First Posted: October 7, 2019    Key Record Dates
Last Update Posted: July 21, 2021
Last Verified: May 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Keywords provided by Carmat SA:
Heart Replacement Therapy
Total Artificial Heart
Biventricular Heart Failure
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases